![Mark J. Bamberger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Mark J.
Bamberger worked as the Director of Cardiovascular Disease Research at Pfizer Inc. from 2004 to 2008.
He also served as the Chief Scientific Officer at Stealth BioTherapeutics Corp.
from 2014 to 2020.
Bamberger received his undergraduate degree from St. Joseph's University in 1974 and his doctorate from Drexel University College of Medicine.
Eerdere bekende functies van Mark J. Bamberger
| Bedrijven | Functie | Einde |
|---|---|---|
| STEALTH BIOTHERAPEUTICS CORP | Hoofd Techniek/Wetenschap/O&O | 01-01-2020 |
| PFIZER INC. | Corporate Officer/Principal | 01-01-2008 |
Opleiding van Mark J. Bamberger
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
83
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
St. Joseph's University
 St. Joseph's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Drexel University College of Medicine
 Drexel University College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stealth BioTherapeutics Corp.
 Stealth BioTherapeutics Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops investigational drugs for the treatment of diseases involving mitochondrial dysfunction | Health Technology |
